Pyelonephritis

The Global Urinary Tract Infection Market is expected to grow from USD 6,449.03 Million in 2018 to USD 9,883.48 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.28%

Retrieved on: 
Friday, April 24, 2020
Medical specialties, Medicine, Infectious diseases, RTT, Urinary tract infection, Pyelonephritis, Urologic disease, Dysuria

On the basis of Clinical Indication, the Global Urinary Tract Infection Market is studied across Cystitis, Pyelonephritis, and Urethritis.

Key Points: 
  • On the basis of Clinical Indication, the Global Urinary Tract Infection Market is studied across Cystitis, Pyelonephritis, and Urethritis.
  • On the basis of End User, the Global Urinary Tract Infection Market is studied across Hospitals and Self-Administered.
  • What are the factors that affect the growth in the Global Urinary Tract Infection Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Urinary Tract Infection Market?

Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 8, 2020
Medical specialties, Medicine, RTT, Antibiotics, Epoxides, Fosfomycin, Urinary tract infection, Pyelonephritis

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

Key Points: 
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection

Retrieved on: 
Wednesday, January 8, 2020
Medical specialties, Medicine, RTT, Health, Antibiotics, Epoxides, Fosfomycin, Urinary tract infection, Pyelonephritis, Infection, Ceftazidime/avibactam

CONTEPO is a potential first-in-class intravenous antibiotic in the U.S. for the treatment of cUTIs.

Key Points: 
  • CONTEPO is a potential first-in-class intravenous antibiotic in the U.S. for the treatment of cUTIs.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for intravenous use in the United States for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Global Pyelonephritis Study 2019: Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 9, 2019
Infectious diseases, Pharmaceutical, Health, Medical specialties, Medicine, Nephrology, Pyelonephritis, RTT, Urinary tract infection

The "Pyelonephritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pyelonephritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections

Retrieved on: 
Wednesday, October 16, 2019
General Health, FDA, Infectious diseases, Health, Pharmaceutical, Medical specialties, Medicine, Health, RTT, Urinary tract infection, Antibiotic, Cephalosporin, Shionogi, Cefiderocol, Pyelonephritis, Plazomicin, Cefiderocol–An Investigational Antibiotic Agent, Gram-negative Infections, Shionogi

Shionogi & Co., Ltd. (hereafter Shionogi) today announced that the U.S. Food and Drug Administrations (FDA) Antimicrobial Drugs Advisory Committee voted to recommend approval of the investigational antibiotic cefiderocol for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in patients with limited or no alternative treatment options.

Key Points: 
  • Shionogi & Co., Ltd. (hereafter Shionogi) today announced that the U.S. Food and Drug Administrations (FDA) Antimicrobial Drugs Advisory Committee voted to recommend approval of the investigational antibiotic cefiderocol for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in patients with limited or no alternative treatment options.
  • We are pleased with the positive recommendation for the approval of cefiderocol for the treatment of cUTI.
  • If approved, we believe cefiderocol could help address a significant unmet need in an area with limited treatment options to fight these life-threatening infections.
  • Cefiderocol is a siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains.